

DOI:10.19803/j.1672-8629.20230298

1	1	1	1	2	2	3	4	5	6	7	8
6* 1					100020 ²	,				100020 ³	
			100020 ⁴						100020 ⁵		
		100020 ⁶						100020 ⁷			
	100020 ⁸						100084				

trodon for injection
a

[1-2] a

[4-6]

Я a

1
1.1

2
Table 2 Distribution of departments for inpatients of haemocoagulase agkistrodon for injection in children

	/	/%
	14 728	41.23
	10 986	30.76
	5 022	14.06
	4 706	13.17
	278	0.78
	35 720	100.00

2 d 736	2.06%	Я d 88	0.25%
3 d 10	0.03%		
		6 d a	
			4 103
99.56%	12	0.29% a	
		99.56% a	
			5 806

427		5		1 U	99.45%
1.3%		a5	0.5 U	1 U	97.97% a
	Я	Я	Я		4 a
		0.008	Я0.003	Я	Kendall
0.003	Я0.003	a		=0.008,	0.5
	5		Г	Е	a 1
4		1		0.5 U 1	1 U
a4			2	2 U	3 U a
			3		
0.5 h		5			
	3 a				I

2.3 给药情况的相关性分析

	Я		[8-9]
	a	35 720	
1 d	34 886	97.67%	

3
Table 3 Adverse drug reactions and related manifestations of haemocoagulase agkistrodon for injection in children

	11 h	Я	Я	Я	Я
	5 m 22 d		Я	Я	Я
Я	2 m 18 d	Я	Я		
	6 y				
	4 y				

4
Table 4 Dosing statistics by different age groups of haemocoagulase agkistrodon for injection in children

	/U						/%
	0.5	0.5	0.5~	1	1	1	
≤ 28 d	35	256	1		37	0	5.67
29 d~1 y	43	842	1		552	2	24.80
1 y~ 3 y	5	451	0		1 398	8	32.07
3 y~ 7 y	0	86	1		1 165	4	21.63
7 y~ 12 y	0	14	0		731	14	13.07
12 y~ 18 y	0	0	0		156	4	2.76
	83	1 649	3		4 039	32	100.00

[10] a

[2] ZHANG ZB, HH, XIE WY. The safety and effectiveness of agkistrodon hemocoagulase i as

[11-12]

[12] a

35 720 5

0.14%

CIOMS

0.01% a

[2]

3 d

a

a

a

Я

[13-15] a

a

[1] BAO L. A research on the safety of haemocoagulase agkistrodon application in premature infant[J]. China Medicine(), 2012, 7(3): 356-357.